1513.HK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 16:08):

Stats
今日成交量	846 183
平均成交量	662 061
市值	35.17B
EPS	HKD0.500 ( 2023-10-24 )
Last Dividend	HKD1.744 ( 2023-07-04 )
Next Dividend	HKD0 ( N/A )
P/E	11.96
ATR14	HKD0.0620 (0.23%)

音量相关性

長: 0.08 (neutral)

短: 0.14 (neutral)

Signal:(57.6) Neutral

Livzon Pharmaceutical 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Livzon Pharmaceutical 相关性 - 货币/商品

-0.73
( moderate negative )

-0.30
( neutral )

0.00
( neutral )

-0.85
( strong negative )

0.35
( neutral )

0.83
( strong )

Livzon Pharmaceutical 财务报表

Annual	2023
营收:	HKD12.43B
毛利润:	HKD7.96B (64.08 %)
EPS:	HKD2.10

FY	2023
营收:	HKD12.43B
毛利润:	HKD7.96B (64.08 %)
EPS:	HKD2.10

FY	2022
营收:	HKD12.63B
毛利润:	HKD8.17B (64.68 %)
EPS:	HKD2.04

FY	2021
营收:	HKD12.06B
毛利润:	HKD7.81B (64.75 %)
EPS:	HKD1.900

Financial Reports:

No articles found.

Livzon Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD1.744 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Livzon Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.98 - good (99.81%) | Divividend Growth Potential Score: 6.52 - Stable (30.36%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.221	2014-07-08
Last Dividend	HKD1.744	2023-07-04
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	HKD9.31	--
Avg. Dividend % Per Year	0.00%	--
Score	3.07	--
Div. Sustainability Score	9.98
Div.Growth Potential Score	6.52
Div. Directional Score	8.25	--

Next Divdend (Est)
(2024-06-24)

HKD1.912 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.07

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
9869.HK	Ex Dividend Junior	2023-09-19	Insufficient data to determine frequency	0.00%
2130.HK	Ex Dividend Knight	2023-06-16	Semi-Annually	0.00%
1126.HK	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
0189.HK	Ex Dividend Junior	2023-06-14	Annually	0.00%
3836.HK	Ex Dividend Junior	2023-06-16	Annually	0.00%
1710.HK	Ex Dividend Junior	2023-09-25	Annually	0.00%
0737.HK	Ex Dividend Knight	2023-09-21	Semi-Annually	0.00%
2314.HK	Ex Dividend Junior	2023-08-11	Semi-Annually	0.00%
1278.HK	Ex Dividend Junior	2023-08-28	Sporadic	0.00%
0327.HK	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.161	1.500	6.77	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0786	1.200	7.38	8.86	[0 - 0.3]
returnOnEquityTTM	0.142	1.500	9.53	10.00	[0.1 - 1]
payoutRatioTTM	0.799	-1.000	2.01	-2.01	[0 - 1]
currentRatioTTM	2.06	0.800	4.69	3.75	[1 - 3]
quickRatioTTM	1.802	0.800	4.11	3.29	[0.8 - 2.5]
cashRatioTTM	1.338	1.500	3.68	5.52	[0.2 - 2]
debtRatioTTM	0.141	-1.500	7.64	-10.00	[0 - 0.6]
interestCoverageTTM	24.70	1.000	1.962	1.962	[3 - 30]
operatingCashFlowPerShareTTM	4.14	2.00	8.62	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.25	2.00	8.37	10.00	[0 - 20]
debtEquityRatioTTM	0.244	-1.500	9.02	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.645	1.000	2.58	2.58	[0.2 - 0.8]
operatingProfitMarginTTM	0.206	1.000	7.88	7.88	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.087	1.000	5.07	5.07	[0.2 - 2]
assetTurnoverTTM	0.487	0.800	-0.0887	-0.0709	[0.5 - 2]
Total Score				9.98

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	12.05	1.000	8.88	0	[1 - 100]
returnOnEquityTTM	0.142	2.50	9.70	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.25	2.00	8.92	10.00	[0 - 30]
dividendYielPercentageTTM	6.84	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.14	2.00	8.62	10.00	[0 - 30]
payoutRatioTTM	0.799	1.500	2.01	-2.01	[0 - 1]
pegRatioTTM	1.132	1.500	5.79	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.316	1.000	4.60	0	[0.1 - 0.5]
Total Score				6.52

Livzon Pharmaceutical

Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.